<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02269917</url>
  </required_header>
  <id_info>
    <org_study_id>CR105736</org_study_id>
    <secondary_id>TMC114IFD3013</secondary_id>
    <secondary_id>2014-003052-31</secondary_id>
    <nct_id>NCT02269917</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants</brief_title>
  <official_title>A Phase 3, Randomized, Active-controlled, Open-label Study to Evaluate the Efficacy, Safety and Tolerability of Switching to a Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF) Once-daily Single-tablet Regimen Versus Continuing the Current Regimen Consisting of a Boosted Protease Inhibitor (bPI) Combined With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) in Virologically-suppressed, Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen R&amp;D Ireland</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen R&amp;D Ireland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate non-inferiority in efficacy while switching to a
      once-daily single-tablet regimen containing darunavir (DRV)/ cobicistat (COBI)/ emtricitabine
      (FTC)/ tenofovir alafenamide (TAF) (D/C/F/TAF tablet) relative to continuing the current
      regimen consisting of a boosted protease inhibitor (bPI) combined with tenofovir disoproxil
      fumarate (FTC/TDF) in virologically-suppressed (human immunodeficiency virus type 1
      ribonucleic acid [HIV-1 RNA] concentrations less than [&lt;] 50 copies per milliliter
      [copies/mL]) HIV-1 infected participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized (study medication assigned to participants by chance), active-controlled
      (study in which the experimental treatment or procedure is compared to a standard treatment
      or procedure), open-label (participants and researchers are aware about the treatment,
      participants are receiving), multicenter (when more than 1 hospital or medical school team
      work on a medical research study), study in virologically-suppressed, HIV-1 infected adult
      participants. The study will include a Screening Period of approximately 30 days (up to
      maximum 6 weeks), a controlled Treatment Period of 48 weeks, an Extension Phase of 48 weeks.
      All eligible participants will be randomly assigned to receive either current treatment
      regimen - a bPI (limited to DRV with low-dose ritonavir [rtv] or COBI, atazanavir [ATV] with
      rtv or COBI, or lopinavir [LPV] with rtv) combined with FTC/TDF, or experimental treatment
      regimen - D/C/F/TAF once-daily single-tablet for 48 weeks. After completion of week 48,
      participants assigned to the experimental treatment will continue with D/C/F/TAF in the
      extension phase up to week 96 . Participants who continued their current regimen will receive
      the experimental treatment (if all criteria are fulfilled) at week 52 up to week 96. As from
      Week 96, all participants will be given the option to continue D/C/F/TAF treatment, if they
      wish and if they continue to benefit from it until D/C/F/TAF becomes commercially available
      and is reimbursed, or can be accessed through another source in the country where he/she is
      living,or until the sponsor terminates clinical development. A bone investigation substudy
      will be performed at selected study sites, to assess bone biomarkers and energy x-ray
      absorptiometry (DXA) scans, in approximately 300 participants (200 in the D/C/F/TAF treatment
      arm versus 100 in the control arm) who provide informed consent for the substudy.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 30, 2015</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Actual">February 17, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Virologic Rebound (HIV-1 RNA &gt;=50 Copies/mL) Cumulative Through Week 48</measure>
    <time_frame>Through Week 48</time_frame>
    <description>Virologic rebound was defined as: confirmed plasma human immunodeficiency virus - 1 (HIV-1) Ribonucleic Acid (RNA) level greater than or equal to (&gt;=)50 copies per milliliter (copies/mL) up to, and including the upper bound of the Week 48 window (ie, 54 weeks) and last available on-treatment (single) HIV-1 RNA &gt;=50 copies/mL at premature discontinuation (irrespective of reason). Percentage of participants with virologic rebound were reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Virologic Rebound (Plasma HIV-1 RNA &gt;=20 Copies/mL) Cumulative Through 48 Weeks</measure>
    <time_frame>Through 48 Weeks</time_frame>
    <description>Virologic rebound was defined as: confirmed plasma HIV-1 RNA &gt;=20 copies/mL up to, and including the upper bound of the Week 48 window (ie, 54 weeks) and last available on-treatment (single) HIV-1 RNA &gt;=20 copies/mL at premature discontinuation (irrespective of reason). Percentage of participants with virologic rebound were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Virologic Rebound (Plasma HIV-1 RNA &gt;=200 Copies/mL) Cumulative Through 48 Weeks</measure>
    <time_frame>Through 48 Weeks</time_frame>
    <description>Virologic rebound was defined as: confirmed plasma HIV-1 RNA &gt;=200 copies/mL up to, and including the upper bound of the Week 48 window (ie, 54 weeks) and last available on-treatment (single) HIV-1 RNA &gt;=200 copies/mL at premature discontinuation (irrespective of reason). Percentage of participants with virologic rebound were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Virologic Rebound</measure>
    <time_frame>Baseline up to Week 48</time_frame>
    <description>Time to virologic rebound was calculated from baseline until the first rebound time point (that is, time point before confirmation of rebound). Virologic rebound was defined as: confirmed plasma HIV-1 RNA &gt;=50 copies/mL up to, and including the upper bound of the Week 48 window (ie, 54 weeks) and last available on-treatment (single) HIV-1 RNA &gt;=50 copies/mL at premature discontinuation (irrespective of reason).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Grade 3 and 4 Adverse Events (AEs)</measure>
    <time_frame>Up to Week 48</time_frame>
    <description>An AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Grade 3 (Severe) events were symptoms causing inability to perform usual social &amp; functional activities. Grade 4 (Life-threatening) events were symptoms causing inability to perform basic self-care functions or medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Creatinine Levels at Weeks 24 and 48</measure>
    <time_frame>Baseline and Weeks 24 and 48</time_frame>
    <description>Change from baseline in serum creatinine levels at Weeks 24 and 48 was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Creatinine (eGFRcr, by Cockcroft-Gault Formula [eGFRcg]) at Weeks 24 and 48</measure>
    <time_frame>Baseline, Weeks 24 and 48</time_frame>
    <description>Change from baseline in eGFRcr (by Cockcroft-Gault formula) was assessed at Weeks 24 and 48. eGFRcr according to the Cockcroft Gault formula- Male: (140 - age in years)*(weight in kilogram [kg])/72*(serum creatinine in milligram per deciliter [mg/dL])=eGFRcr (milliliter per minute [mL/min]); Female: (140 - age in years)*(weight in kg)/72*(serum creatinine in mg/dL)*0.85=eGFRcr (mL/min).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Creatinine (eGFRcr, by Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) at Weeks 24 and 48</measure>
    <time_frame>Baseline, Weeks 24 and 48</time_frame>
    <description>Change from baseline in eGFRcr (by CKD-EPI) was assessed at Weeks 24 and 48. eGFRcr per CKD-EPI formula - Female: 1) Serum creatinine (Scr) less than or equal to (&lt;=)0.7 mg/dL: 144*(Scr/0.7)^-0.329*0.993age; 2) Scr greater than (&gt;)0.7 mg/dL: 144*(Scr/0.7)^-1.209*0.993age. Male: 1) Scr &lt;=0.9 mg/dL: 141*(Scr/0.9)^-0.411*0.993age; 2) Scr &gt;0.9 mg/dL: 141*(Scr/0.9)^-1.209*0.993age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Cystatin C (eGFRcyst, by Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) at Weeks 24 and 48</measure>
    <time_frame>Baseline, Weeks 24 and 48</time_frame>
    <description>Change from baseline in eGFRcyst (by CKD-EPI) was assessed at Weeks 24 and 48. eGFRcyst according to the CKD-EPI formula - 1) Serum Cystatin C (Scyst) &lt;=0.8 mg/L: 133*(Scyst/0.8)^-0.499*0.996age (*0.932 if female); 2) Scyst &gt;0.8 mg/L: 133*(Scyst/0.8)^-1.328*0.996age (*0.932 if female).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urine Albumin to Creatinine Ratio (UACR) and Urine Protein to Creatinine Ratio (UPCR) at Weeks 24 and 48</measure>
    <time_frame>Baseline, Weeks 24 and 48</time_frame>
    <description>Change from baseline in UACR and UPCR was assessed at Weeks 24 and 48. Lower levels of albumin or protein in the urine indicates better proximal tubular function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urine Retinol Binding Protein to Creatinine Ratio (URBPCR) and Urine Beta-2 Microglobulin to Creatinine Ratio (UB2MGCR) at Weeks 24 and 48</measure>
    <time_frame>Baseline, Weeks 24 and 48</time_frame>
    <description>Change from baseline in URBPCR and UB2MGCR was assessed at Weeks 24 and 48. Retinol binding protein is a marker of proximal tubular function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Urine Fractional Excretion of Phosphate (FEPO4) at Weeks 24 and 48</measure>
    <time_frame>Baseline, Weeks 24 and 48</time_frame>
    <description>Percent change from baseline in urine FEPO4 was assessed at Weeks 24 and 48.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Virologic Response Based on HIV-1 RNA Less Than (&lt;)20, &lt;50, and &lt;200 Copies/mL Threshold at Week 48 as Defined by the Food and Drug Administration (FDA) Snapshot Approach</measure>
    <time_frame>Week 48</time_frame>
    <description>Percentage of participants with virologic response based on HIV-1 RNA &lt;20, &lt;50, and &lt;200 copies/mL threshold were analyzed at Week 48 using FDA snapshot approach. FDA Snapshot approach analysis was based on the last observed viral load data: virologic response was defined as HIV-1 RNA &lt;20/50/200 copies/mL (observed case).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Virologic Response Based on HIV-1 RNA &lt;20, &lt;50, and &lt;200 Copies/mL Threshold at Week 48 as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm</measure>
    <time_frame>Week 48</time_frame>
    <description>Percentage of participants with virologic response based on HIV-1 RNA &lt;20, &lt;50, and &lt;200 copies/mL threshold were analyzed at Week 48 using TLOVR algorithm approach. TLOVR was defined as sustained HIV-1 RNA &lt;20/50/200 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cluster of Differentiation 4 Plus (CD4+) Cell Count at Weeks 24 and 48</measure>
    <time_frame>Baseline, Weeks 24 and 48</time_frame>
    <description>Change from baseline in CD4+ cell count was assessed at Weeks 24 and 48.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Treatment Adherence of Greater Than (&gt;)95 Percent (%) (Approach 1) Through Week 48</measure>
    <time_frame>Through Week 48</time_frame>
    <description>Treatment adherence (defined as adherence of &gt;95%) was assessed by the drug accountability cumulative through Week 48 (Approach 1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Treatment Adherence of &gt;95% (Approach 2) Through Week 48</measure>
    <time_frame>Through Week 48</time_frame>
    <description>Treatment adherence (defined as adherence of &gt;95%) was assessed by the drug accountability cumulative treatment adherence up to time point where not more than one bottle was missing, or if available, through Week 48, whichever came sooner (Approach 2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Resistance to Study Drug</measure>
    <time_frame>Up to Week 48</time_frame>
    <description>HIV-1 genotypes were analyzed from samples of participants with confirmed virologic rebound (virologic rebound was defined as: confirmed HIV-1 RNA &gt;=50 copies/mL up to, and including the upper bound of the Week 48 window) and with HIV-1 RNA value greater than or equal to (&gt;=)400 copies/mL or who discontinued with last HIV-1 RNA &gt;=400 copies/mL. Number of participants who developed resistance to any of the study drug was determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predose (Trough) Plasma Concentration (C0h) of Darunavir</measure>
    <time_frame>Predose at Weeks 2, 4, 8, 12, 24, 36, and 48</time_frame>
    <description>Predose (trough) plasma concentration (C0h) of darunavir was determined. Pharmacokinetic (PK) data was only analyzed for participants in the D/C/F/TAF group as per planned analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Serum Procollagen 1 N-Terminal Propeptide (P1NP) and Serum Collagen Type 1 Beta Carboxy Telopeptide (CTX) Levels at Weeks 24 and 48</measure>
    <time_frame>Baseline, Weeks 24 and 48</time_frame>
    <description>Percent change from baseline in bone biomarkers: P1NP and CTX was assessed at Weeks 24 and 48.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Parathyroid Hormone (PTH) at Weeks 24 and 48</measure>
    <time_frame>Baseline, Weeks 24 and 48</time_frame>
    <description>Percent change from baseline in bone biomarker: PTH was assessed at Weeks 24 and 48.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in 25-hydroxy Vitamin D at Weeks 24 and 48</measure>
    <time_frame>Baseline, Weeks 24 and 48</time_frame>
    <description>Percent change from baseline in bone biomarker: 25-hydroxy vitamin D was assessed at Weeks 24 and 48.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Spine and Hip Bone Mineral Density (BMD) at Weeks 24 and 48</measure>
    <time_frame>Baseline, Weeks 24 and 48</time_frame>
    <description>Percent change from baseline in spine and hip BMD was assessed at Weeks 24 and 48.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Bone Mineral Density (BMD) T-Score at Weeks 24 and 48</measure>
    <time_frame>Baseline, Weeks 24 and 48</time_frame>
    <description>Change from baseline in spine, hip, and femoral neck BMD T-Score was assessed at Week 24 and 48. T-score values &gt;= -1.0 were considered normal, T-score values &lt; -1.0 to -2.5 indicate osteopenia and T-score values &lt; -2.5 indicate osteoporosis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1149</enrollment>
  <condition>Human Immunodeficiency Virus Type 1</condition>
  <arm_group>
    <arm_group_label>Experimental Treatment Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single fixed dose combination (FDC) tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF tablet), orally once daily, up to Week 48. After Week 48, all participants will continue to receive the D/C/F/TAF tablet in a 48 week extension phase (up to Week 96).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Current Treatment Regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive a boosted protease inhibitor (bPI) (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) combined with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) up to Week 52. After Week 52, all participants will receive the D/C/F/TAF tablet in a 44 week extension phase (up to Week 96).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D/C/F/TAF</intervention_name>
    <description>Once-daily single-tablet regimen containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg.</description>
    <arm_group_label>Experimental Treatment Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Boosted Protease Inhibitor (bPI)</intervention_name>
    <description>Boosted protease inhibitor (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) as per current treatment regimen.</description>
    <arm_group_label>Current Treatment Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FTC/TDF</intervention_name>
    <description>Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF).</description>
    <arm_group_label>Current Treatment Regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Currently being treated with a stable antiretroviral (ARV) regimen consisting of a
             boosted protease inhibitor (limited to darunavir [DRV] or atazanavir with low-dose
             ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) combined with
             emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) only, for at least 6 consecutive
             months preceding the Screening visit

          -  On-treatment plasma human immunodeficiency virus type 1 ribonucleic acid (HIV-1 RNA)
             concentrations less than (&lt;) 50 copies per milliliter (copies/mL) or HIV-1 RNA
             undetectable by a local HIV-1 RNA test between 12 and 2 months prior to the Screening
             visit and have HIV-1 RNA &lt;50 copies/mL at the Screening visit

          -  A single virologic elevation of greater than or equal to (&gt;=) 50 copies/mL after
             previously reaching viral suppression between 12 and 2 months prior to Screening is
             acceptable, provided a subsequent test prior to Screening was &lt;50 copies/mL

          -  Absence of history of failure on DRV treatment and absence of DRV
             resistance-associated mutations (RAMs), if documented historical genotypes are
             available

          -  Normal electrocardiogram (ECG) at Screening (or if abnormal, determined by the
             Investigator to be not clinically significant)

        Exclusion Criteria:

          -  A new acquired immunodeficiency syndrome (AIDS) - defining condition diagnosed within
             the 30 days prior to Screening

          -  Proven or suspected acute hepatitis within 30 days prior to study entry

          -  Hepatitis C antibody positive; however, participants previously cured of hepatitis C
             virus (HCV) infection, with documented sustained virologic response, that is,
             undetectable HCV RNA 24 weeks after the last dose of HCV treatment, are allowed to
             participate

          -  Hepatitis B surface antigen (HBsAg) positive

          -  Participants with cirrhosis as diagnosed based on local practices
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen R&amp;D Ireland Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen R&amp;D Ireland</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berkley</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hillsborough</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Somers Point</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Fe</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Le Kremlin Bicetre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris Cedex 10</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris Cedex 12</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Strasbourg Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tourcoing</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chorzow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cordoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elche</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Sebastian</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zurich N/a</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
    <country>Romania</country>
    <country>Russian Federation</country>
  </removed_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 17, 2014</study_first_submitted>
  <study_first_submitted_qc>October 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2014</study_first_posted>
  <results_first_submitted>August 14, 2018</results_first_submitted>
  <results_first_submitted_qc>November 8, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 9, 2018</results_first_posted>
  <disposition_first_submitted>February 8, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>February 8, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 12, 2018</disposition_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human Immunodeficiency Virus Type 1</keyword>
  <keyword>Emerald</keyword>
  <keyword>Darunavir</keyword>
  <keyword>Cobicistat</keyword>
  <keyword>Emtricitabine</keyword>
  <keyword>Tenofovir Alafenamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Protease Inhibitors</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 5, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT02269917/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 29, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT02269917/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Results are reported through Week 48 (primary analysis). Complete data through final analysis (including extension through Week 96 and follow-up) will be reported within 1 year of end of trial date when final data based on study completion date will be available. Total 1149 participants were randomized out of which 1141 were treated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>D/C/F/TAF</title>
          <description>Participants received a single fixed dose combination (FDC) tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF tablet), orally once daily up to Week 48.</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Participants received a boosted protease inhibitor (bPI) (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) combined with emtricitabine/tenofovir disoproxil fumarate (F/TDF) up to Week 48.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="766"/>
                <participants group_id="P2" count="383"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="763"/>
                <participants group_id="P2" count="378"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="766"/>
                <participants group_id="P2" count="383"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="731"/>
                <participants group_id="P2" count="360"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but not treated</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat (ITT) analysis set included all the participants who were randomized and received at least 1 dose of study treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>D/C/F/TAF</title>
          <description>Participants received a single fixed dose combination (FDC) tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF tablet), orally once daily up to Week 48.</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Participants received a boosted protease inhibitor (bPI) (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) combined with emtricitabine/tenofovir disoproxil fumarate (F/TDF) up to Week 48.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="763"/>
            <count group_id="B2" value="378"/>
            <count group_id="B3" value="1141"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.3" spread="10.86"/>
                    <measurement group_id="B2" value="44.8" spread="10.77"/>
                    <measurement group_id="B3" value="45.1" spread="10.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="205"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="623"/>
                    <measurement group_id="B2" value="313"/>
                    <measurement group_id="B3" value="936"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="170"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="649"/>
                    <measurement group_id="B2" value="317"/>
                    <measurement group_id="B3" value="966"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="237"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="573"/>
                    <measurement group_id="B2" value="282"/>
                    <measurement group_id="B3" value="855"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="476"/>
                    <measurement group_id="B2" value="225"/>
                    <measurement group_id="B3" value="701"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="313"/>
                    <measurement group_id="B2" value="181"/>
                    <measurement group_id="B3" value="494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Virologic Rebound (HIV-1 RNA &gt;=50 Copies/mL) Cumulative Through Week 48</title>
        <description>Virologic rebound was defined as: confirmed plasma human immunodeficiency virus - 1 (HIV-1) Ribonucleic Acid (RNA) level greater than or equal to (&gt;=)50 copies per milliliter (copies/mL) up to, and including the upper bound of the Week 48 window (ie, 54 weeks) and last available on-treatment (single) HIV-1 RNA &gt;=50 copies/mL at premature discontinuation (irrespective of reason). Percentage of participants with virologic rebound were reported.</description>
        <time_frame>Through Week 48</time_frame>
        <population>Intent-to-treat (ITT) analysis set included all the participants who were randomized and received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF</title>
            <description>Participants received a single fixed dose combination (FDC) tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF tablet), orally once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received a boosted protease inhibitor (bPI) (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) combined with emtricitabine/tenofovir disoproxil fumarate (F/TDF) up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Virologic Rebound (HIV-1 RNA &gt;=50 Copies/mL) Cumulative Through Week 48</title>
          <description>Virologic rebound was defined as: confirmed plasma human immunodeficiency virus - 1 (HIV-1) Ribonucleic Acid (RNA) level greater than or equal to (&gt;=)50 copies per milliliter (copies/mL) up to, and including the upper bound of the Week 48 window (ie, 54 weeks) and last available on-treatment (single) HIV-1 RNA &gt;=50 copies/mL at premature discontinuation (irrespective of reason). Percentage of participants with virologic rebound were reported.</description>
          <population>Intent-to-treat (ITT) analysis set included all the participants who were randomized and received at least 1 dose of study treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="763"/>
                <count group_id="O2" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="1.5" upper_limit="3.9"/>
                    <measurement group_id="O2" value="2.1" lower_limit="0.9" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>4</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Stratum-adjusted Mantel-Haenszel (MH)</method>
            <param_type>Difference in percentage</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Virologic Rebound (Plasma HIV-1 RNA &gt;=20 Copies/mL) Cumulative Through 48 Weeks</title>
        <description>Virologic rebound was defined as: confirmed plasma HIV-1 RNA &gt;=20 copies/mL up to, and including the upper bound of the Week 48 window (ie, 54 weeks) and last available on-treatment (single) HIV-1 RNA &gt;=20 copies/mL at premature discontinuation (irrespective of reason). Percentage of participants with virologic rebound were reported.</description>
        <time_frame>Through 48 Weeks</time_frame>
        <population>ITT analysis set included all participants who were randomized and received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF</title>
            <description>Participants received a single fixed dose combination (FDC) tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF tablet), orally once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received a boosted protease inhibitor (bPI) (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) combined with emtricitabine/tenofovir disoproxil fumarate (F/TDF) up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Virologic Rebound (Plasma HIV-1 RNA &gt;=20 Copies/mL) Cumulative Through 48 Weeks</title>
          <description>Virologic rebound was defined as: confirmed plasma HIV-1 RNA &gt;=20 copies/mL up to, and including the upper bound of the Week 48 window (ie, 54 weeks) and last available on-treatment (single) HIV-1 RNA &gt;=20 copies/mL at premature discontinuation (irrespective of reason). Percentage of participants with virologic rebound were reported.</description>
          <population>ITT analysis set included all participants who were randomized and received at least 1 dose of study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="763"/>
                <count group_id="O2" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" lower_limit="8.4" upper_limit="12.9"/>
                    <measurement group_id="O2" value="11.4" lower_limit="8.4" upper_limit="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Virologic Rebound (Plasma HIV-1 RNA &gt;=200 Copies/mL) Cumulative Through 48 Weeks</title>
        <description>Virologic rebound was defined as: confirmed plasma HIV-1 RNA &gt;=200 copies/mL up to, and including the upper bound of the Week 48 window (ie, 54 weeks) and last available on-treatment (single) HIV-1 RNA &gt;=200 copies/mL at premature discontinuation (irrespective of reason). Percentage of participants with virologic rebound were reported.</description>
        <time_frame>Through 48 Weeks</time_frame>
        <population>ITT analysis set included all participants who were randomized and received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF</title>
            <description>Participants received a single fixed dose combination (FDC) tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF tablet), orally once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received a boosted protease inhibitor (bPI) (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) combined with emtricitabine/tenofovir disoproxil fumarate (F/TDF) up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Virologic Rebound (Plasma HIV-1 RNA &gt;=200 Copies/mL) Cumulative Through 48 Weeks</title>
          <description>Virologic rebound was defined as: confirmed plasma HIV-1 RNA &gt;=200 copies/mL up to, and including the upper bound of the Week 48 window (ie, 54 weeks) and last available on-treatment (single) HIV-1 RNA &gt;=200 copies/mL at premature discontinuation (irrespective of reason). Percentage of participants with virologic rebound were reported.</description>
          <population>ITT analysis set included all participants who were randomized and received at least 1 dose of study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="763"/>
                <count group_id="O2" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.1" upper_limit="1.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="NA" upper_limit="NA">Here NA signifies that the Confidence Interval (CI) was not estimable as no participants had virologic rebound in this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Virologic Rebound</title>
        <description>Time to virologic rebound was calculated from baseline until the first rebound time point (that is, time point before confirmation of rebound). Virologic rebound was defined as: confirmed plasma HIV-1 RNA &gt;=50 copies/mL up to, and including the upper bound of the Week 48 window (ie, 54 weeks) and last available on-treatment (single) HIV-1 RNA &gt;=50 copies/mL at premature discontinuation (irrespective of reason).</description>
        <time_frame>Baseline up to Week 48</time_frame>
        <population>ITT analysis set included all participants who were randomized and received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF</title>
            <description>Participants received a single fixed dose combination (FDC) tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF tablet), orally once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received a boosted protease inhibitor (bPI) (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) combined with emtricitabine/tenofovir disoproxil fumarate (F/TDF) up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Virologic Rebound</title>
          <description>Time to virologic rebound was calculated from baseline until the first rebound time point (that is, time point before confirmation of rebound). Virologic rebound was defined as: confirmed plasma HIV-1 RNA &gt;=50 copies/mL up to, and including the upper bound of the Week 48 window (ie, 54 weeks) and last available on-treatment (single) HIV-1 RNA &gt;=50 copies/mL at premature discontinuation (irrespective of reason).</description>
          <population>ITT analysis set included all participants who were randomized and received at least 1 dose of study treatment.</population>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="763"/>
                <count group_id="O2" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">The median and confidence interval (CI - lower or upper limit) could not be estimated due to low number of rebounders.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">The median and confidence interval (CI - lower or upper limit) could not be estimated due to low number of rebounders.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Experiencing Grade 3 and 4 Adverse Events (AEs)</title>
        <description>An AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Grade 3 (Severe) events were symptoms causing inability to perform usual social &amp; functional activities. Grade 4 (Life-threatening) events were symptoms causing inability to perform basic self-care functions or medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death.</description>
        <time_frame>Up to Week 48</time_frame>
        <population>ITT analysis set included all the participants who were randomized and received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF</title>
            <description>Participants received a single fixed dose combination (FDC) tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF tablet), orally once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received a boosted protease inhibitor (bPI) (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) combined with emtricitabine/tenofovir disoproxil fumarate (F/TDF) up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing Grade 3 and 4 Adverse Events (AEs)</title>
          <description>An AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Grade 3 (Severe) events were symptoms causing inability to perform usual social &amp; functional activities. Grade 4 (Life-threatening) events were symptoms causing inability to perform basic self-care functions or medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death.</description>
          <population>ITT analysis set included all the participants who were randomized and received at least 1 dose of study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="763"/>
                <count group_id="O2" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Creatinine Levels at Weeks 24 and 48</title>
        <description>Change from baseline in serum creatinine levels at Weeks 24 and 48 was assessed.</description>
        <time_frame>Baseline and Weeks 24 and 48</time_frame>
        <population>ITT analysis set included all participants randomized and received at least 1 dose of study treatment. Here, N (number of participants analyzed) indicates number of participants evaluable for this endpoint; and ‘n’ specifies participants analyzed for this endpoint at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF</title>
            <description>Participants received a single fixed dose combination (FDC) tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF tablet), orally once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received a boosted protease inhibitor (bPI) (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) combined with emtricitabine/tenofovir disoproxil fumarate (F/TDF) up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Creatinine Levels at Weeks 24 and 48</title>
          <description>Change from baseline in serum creatinine levels at Weeks 24 and 48 was assessed.</description>
          <population>ITT analysis set included all participants randomized and received at least 1 dose of study treatment. Here, N (number of participants analyzed) indicates number of participants evaluable for this endpoint; and ‘n’ specifies participants analyzed for this endpoint at given time point.</population>
          <units>micro mole per liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="761"/>
                <count group_id="O2" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="735"/>
                    <count group_id="O2" value="362"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" spread="0.358"/>
                    <measurement group_id="O2" value="0.88" spread="0.509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="725"/>
                    <count group_id="O2" value="350"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" spread="0.368"/>
                    <measurement group_id="O2" value="0.65" spread="0.530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change at Week 24</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>=0.580</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square (LS) Mean Difference</param_type>
            <param_value>0.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.623</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.88</ci_lower_limit>
            <ci_upper_limit>1.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change at Week 48</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>=0.340</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square (LS) Mean Difference</param_type>
            <param_value>0.62</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.646</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.65</ci_lower_limit>
            <ci_upper_limit>1.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Creatinine (eGFRcr, by Cockcroft-Gault Formula [eGFRcg]) at Weeks 24 and 48</title>
        <description>Change from baseline in eGFRcr (by Cockcroft-Gault formula) was assessed at Weeks 24 and 48. eGFRcr according to the Cockcroft Gault formula- Male: (140 - age in years)*(weight in kilogram [kg])/72*(serum creatinine in milligram per deciliter [mg/dL])=eGFRcr (milliliter per minute [mL/min]); Female: (140 - age in years)*(weight in kg)/72*(serum creatinine in mg/dL)*0.85=eGFRcr (mL/min).</description>
        <time_frame>Baseline, Weeks 24 and 48</time_frame>
        <population>ITT analysis set included all the participants who were randomized and received at least 1 dose of study treatment. Here, N (number of participants analyzed) indicates number of participants evaluable for this endpoint; and ‘n’ specifies those participants who were analyzed for this endpoint at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF</title>
            <description>Participants received a single fixed dose combination (FDC) tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF tablet), orally once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received a boosted protease inhibitor (bPI) (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) combined with emtricitabine/tenofovir disoproxil fumarate (F/TDF) up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Creatinine (eGFRcr, by Cockcroft-Gault Formula [eGFRcg]) at Weeks 24 and 48</title>
          <description>Change from baseline in eGFRcr (by Cockcroft-Gault formula) was assessed at Weeks 24 and 48. eGFRcr according to the Cockcroft Gault formula- Male: (140 - age in years)*(weight in kilogram [kg])/72*(serum creatinine in milligram per deciliter [mg/dL])=eGFRcr (milliliter per minute [mL/min]); Female: (140 - age in years)*(weight in kg)/72*(serum creatinine in mg/dL)*0.85=eGFRcr (mL/min).</description>
          <population>ITT analysis set included all the participants who were randomized and received at least 1 dose of study treatment. Here, N (number of participants analyzed) indicates number of participants evaluable for this endpoint; and ‘n’ specifies those participants who were analyzed for this endpoint at given time point.</population>
          <units>milliliter per minute (mL/min)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="761"/>
                <count group_id="O2" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="735"/>
                    <count group_id="O2" value="362"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.502"/>
                    <measurement group_id="O2" value="0.20" spread="0.715"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="725"/>
                    <count group_id="O2" value="350"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.94" spread="0.492"/>
                    <measurement group_id="O2" value="-0.20" spread="0.708"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change at Week 24</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>=0.506</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.874</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.30</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change Week 48</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>=0.392</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.74</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.862</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.43</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Creatinine (eGFRcr, by Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) at Weeks 24 and 48</title>
        <description>Change from baseline in eGFRcr (by CKD-EPI) was assessed at Weeks 24 and 48. eGFRcr per CKD-EPI formula - Female: 1) Serum creatinine (Scr) less than or equal to (&lt;=)0.7 mg/dL: 144*(Scr/0.7)^-0.329*0.993age; 2) Scr greater than (&gt;)0.7 mg/dL: 144*(Scr/0.7)^-1.209*0.993age. Male: 1) Scr &lt;=0.9 mg/dL: 141*(Scr/0.9)^-0.411*0.993age; 2) Scr &gt;0.9 mg/dL: 141*(Scr/0.9)^-1.209*0.993age.</description>
        <time_frame>Baseline, Weeks 24 and 48</time_frame>
        <population>ITT analysis set included all the participants who were randomized and received at least 1 dose of study treatment. Here, N (number of participants analyzed) indicates number of participants evaluable for this endpoint; and ‘n’ specifies those participants who were analyzed for this endpoint at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF</title>
            <description>Participants received a single fixed dose combination (FDC) tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF tablet), orally once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received a boosted protease inhibitor (bPI) (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) combined with emtricitabine/tenofovir disoproxil fumarate (F/TDF) up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Creatinine (eGFRcr, by Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) at Weeks 24 and 48</title>
          <description>Change from baseline in eGFRcr (by CKD-EPI) was assessed at Weeks 24 and 48. eGFRcr per CKD-EPI formula - Female: 1) Serum creatinine (Scr) less than or equal to (&lt;=)0.7 mg/dL: 144*(Scr/0.7)^-0.329*0.993age; 2) Scr greater than (&gt;)0.7 mg/dL: 144*(Scr/0.7)^-1.209*0.993age. Male: 1) Scr &lt;=0.9 mg/dL: 141*(Scr/0.9)^-0.411*0.993age; 2) Scr &gt;0.9 mg/dL: 141*(Scr/0.9)^-1.209*0.993age.</description>
          <population>ITT analysis set included all the participants who were randomized and received at least 1 dose of study treatment. Here, N (number of participants analyzed) indicates number of participants evaluable for this endpoint; and ‘n’ specifies those participants who were analyzed for this endpoint at given time point.</population>
          <units>mL/min/1.73 m^2</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="761"/>
                <count group_id="O2" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="735"/>
                    <count group_id="O2" value="362"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.67" spread="0.359"/>
                    <measurement group_id="O2" value="-0.75" spread="0.510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="725"/>
                    <count group_id="O2" value="350"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.97" spread="0.369"/>
                    <measurement group_id="O2" value="-0.88" spread="0.531"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change at Week 24</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>=0.143</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.92</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.624</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.14</ci_lower_limit>
            <ci_upper_limit>0.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change at Week 48</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>=0.092</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.646</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.36</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Cystatin C (eGFRcyst, by Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) at Weeks 24 and 48</title>
        <description>Change from baseline in eGFRcyst (by CKD-EPI) was assessed at Weeks 24 and 48. eGFRcyst according to the CKD-EPI formula - 1) Serum Cystatin C (Scyst) &lt;=0.8 mg/L: 133*(Scyst/0.8)^-0.499*0.996age (*0.932 if female); 2) Scyst &gt;0.8 mg/L: 133*(Scyst/0.8)^-1.328*0.996age (*0.932 if female).</description>
        <time_frame>Baseline, Weeks 24 and 48</time_frame>
        <population>ITT analysis set included all the participants who were randomized and received at least 1 dose of study treatment. Here, ‘n’ specifies those participants who were analyzed for this endpoint at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF</title>
            <description>Participants received a single fixed dose combination (FDC) tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF tablet), orally once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received a boosted protease inhibitor (bPI) (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) combined with emtricitabine/tenofovir disoproxil fumarate (F/TDF) up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Cystatin C (eGFRcyst, by Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) at Weeks 24 and 48</title>
          <description>Change from baseline in eGFRcyst (by CKD-EPI) was assessed at Weeks 24 and 48. eGFRcyst according to the CKD-EPI formula - 1) Serum Cystatin C (Scyst) &lt;=0.8 mg/L: 133*(Scyst/0.8)^-0.499*0.996age (*0.932 if female); 2) Scyst &gt;0.8 mg/L: 133*(Scyst/0.8)^-1.328*0.996age (*0.932 if female).</description>
          <population>ITT analysis set included all the participants who were randomized and received at least 1 dose of study treatment. Here, ‘n’ specifies those participants who were analyzed for this endpoint at given time point.</population>
          <units>mL/min/1.73 m^2</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="763"/>
                <count group_id="O2" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>eGFRcyst: Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="734"/>
                    <count group_id="O2" value="360"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.338"/>
                    <measurement group_id="O2" value="-0.93" spread="0.483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>eGFRcyst: Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="724"/>
                    <count group_id="O2" value="351"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="0.360"/>
                    <measurement group_id="O2" value="-1.76" spread="0.517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change at Week 24</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>=0.054</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.590</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.02</ci_lower_limit>
            <ci_upper_limit>2.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change at Week 48</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>=0.034</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.630</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.10</ci_lower_limit>
            <ci_upper_limit>2.57</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Urine Albumin to Creatinine Ratio (UACR) and Urine Protein to Creatinine Ratio (UPCR) at Weeks 24 and 48</title>
        <description>Change from baseline in UACR and UPCR was assessed at Weeks 24 and 48. Lower levels of albumin or protein in the urine indicates better proximal tubular function.</description>
        <time_frame>Baseline, Weeks 24 and 48</time_frame>
        <population>ITT analysis set included all the participants who were randomized and received at least 1 dose of study treatment. Here, N (number of participants analyzed) indicates number of participants evaluable for this endpoint; and ‘n’ specifies those participants who were analyzed for this endpoint at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF</title>
            <description>Participants received a single fixed dose combination (FDC) tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF tablet), orally once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received a boosted protease inhibitor (bPI) (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) combined with emtricitabine/tenofovir disoproxil fumarate (F/TDF) up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urine Albumin to Creatinine Ratio (UACR) and Urine Protein to Creatinine Ratio (UPCR) at Weeks 24 and 48</title>
          <description>Change from baseline in UACR and UPCR was assessed at Weeks 24 and 48. Lower levels of albumin or protein in the urine indicates better proximal tubular function.</description>
          <population>ITT analysis set included all the participants who were randomized and received at least 1 dose of study treatment. Here, N (number of participants analyzed) indicates number of participants evaluable for this endpoint; and ‘n’ specifies those participants who were analyzed for this endpoint at given time point.</population>
          <units>milligram per gram (mg/g)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="761"/>
                <count group_id="O2" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>UACR: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="761"/>
                    <count group_id="O2" value="378"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.20" lower_limit="1.4" upper_limit="632.1"/>
                    <measurement group_id="O2" value="7.14" lower_limit="1.1" upper_limit="268.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UACR: Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="735"/>
                    <count group_id="O2" value="362"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.78" lower_limit="-185.4" upper_limit="422.2"/>
                    <measurement group_id="O2" value="0.44" lower_limit="-238.5" upper_limit="145.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UACR: Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="723"/>
                    <count group_id="O2" value="351"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.76" lower_limit="-195.8" upper_limit="344.3"/>
                    <measurement group_id="O2" value="0.40" lower_limit="-121.7" upper_limit="110.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UPCR: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="375"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.56" lower_limit="16.9" upper_limit="1158.1"/>
                    <measurement group_id="O2" value="62.90" lower_limit="14.7" upper_limit="870.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UPCR: Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="727"/>
                    <count group_id="O2" value="357"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.63" lower_limit="-509.6" upper_limit="734.6"/>
                    <measurement group_id="O2" value="0.07" lower_limit="-359.9" upper_limit="400.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UPCR: Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="710"/>
                    <count group_id="O2" value="347"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.25" lower_limit="-520.1" upper_limit="386.6"/>
                    <measurement group_id="O2" value="-7.37" lower_limit="-368.7" upper_limit="432.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>UACR - Change at Week 24</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Van Elteren Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>UACR - Change at Week 48</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Van Elteren Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>UPCR - Change at Week 24</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Van Elteren Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>UPCR - Change at Week 48</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Van Elteren Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Urine Retinol Binding Protein to Creatinine Ratio (URBPCR) and Urine Beta-2 Microglobulin to Creatinine Ratio (UB2MGCR) at Weeks 24 and 48</title>
        <description>Change from baseline in URBPCR and UB2MGCR was assessed at Weeks 24 and 48. Retinol binding protein is a marker of proximal tubular function.</description>
        <time_frame>Baseline, Weeks 24 and 48</time_frame>
        <population>ITT analysis set included all the participants who were randomized and received at least 1 dose of study treatment. Here, N (number of participants analyzed) indicates number of participants evaluable for this endpoint; and ‘n’ specifies those participants who were analyzed for this endpoint at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF</title>
            <description>Participants received a single fixed dose combination (FDC) tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF tablet), orally once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received a boosted protease inhibitor (bPI) (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) combined with emtricitabine/tenofovir disoproxil fumarate (F/TDF) up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urine Retinol Binding Protein to Creatinine Ratio (URBPCR) and Urine Beta-2 Microglobulin to Creatinine Ratio (UB2MGCR) at Weeks 24 and 48</title>
          <description>Change from baseline in URBPCR and UB2MGCR was assessed at Weeks 24 and 48. Retinol binding protein is a marker of proximal tubular function.</description>
          <population>ITT analysis set included all the participants who were randomized and received at least 1 dose of study treatment. Here, N (number of participants analyzed) indicates number of participants evaluable for this endpoint; and ‘n’ specifies those participants who were analyzed for this endpoint at given time point.</population>
          <units>microgram per gram (mcg/g)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="748"/>
                <count group_id="O2" value="371"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>URBPCR: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="748"/>
                    <count group_id="O2" value="371"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.19" lower_limit="20.3" upper_limit="116216.2"/>
                    <measurement group_id="O2" value="137.16" lower_limit="12.9" upper_limit="73958.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>URBPCR: Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="721"/>
                    <count group_id="O2" value="356"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.27" lower_limit="-69873.2" upper_limit="2004.4"/>
                    <measurement group_id="O2" value="7.76" lower_limit="-6040.1" upper_limit="60740.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>URBPCR: Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="710"/>
                    <count group_id="O2" value="344"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.09" lower_limit="-67540.0" upper_limit="1764.3"/>
                    <measurement group_id="O2" value="19.66" lower_limit="-5778.3" upper_limit="65203.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UB2MGCR: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="736"/>
                    <count group_id="O2" value="366"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156.85" lower_limit="3.8" upper_limit="91216.2"/>
                    <measurement group_id="O2" value="172.25" lower_limit="9.8" upper_limit="92740.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UB2MGCR: Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="702"/>
                    <count group_id="O2" value="348"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-72.64" lower_limit="-72264.6" upper_limit="13536.2"/>
                    <measurement group_id="O2" value="12.08" lower_limit="-20084.8" upper_limit="58357.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UB2MGCR: Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="693"/>
                    <count group_id="O2" value="338"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-67.02" lower_limit="-72323.4" upper_limit="21190.2"/>
                    <measurement group_id="O2" value="20.24" lower_limit="-22173.5" upper_limit="135576.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>URBPCR: Change at Week 24</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Van Elteren Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>URBPCR: Change at Week 48</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Van Elteren Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>UB2MGCR: Change at Week 24</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Van Elteren Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>UB2MGCR: Change at Week 48</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Van Elteren Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Urine Fractional Excretion of Phosphate (FEPO4) at Weeks 24 and 48</title>
        <description>Percent change from baseline in urine FEPO4 was assessed at Weeks 24 and 48.</description>
        <time_frame>Baseline, Weeks 24 and 48</time_frame>
        <population>ITT analysis set included all the participants who were randomized and received at least 1 dose of study treatment. Here ‘n’ specifies those participants who were analyzed for this endpoint at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF</title>
            <description>Participants received a single fixed dose combination (FDC) tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF tablet), orally once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received a boosted protease inhibitor (bPI) (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) combined with emtricitabine/tenofovir disoproxil fumarate (F/TDF) up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Urine Fractional Excretion of Phosphate (FEPO4) at Weeks 24 and 48</title>
          <description>Percent change from baseline in urine FEPO4 was assessed at Weeks 24 and 48.</description>
          <population>ITT analysis set included all the participants who were randomized and received at least 1 dose of study treatment. Here ‘n’ specifies those participants who were analyzed for this endpoint at given time point.</population>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="763"/>
                <count group_id="O2" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="729"/>
                    <count group_id="O2" value="358"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58" lower_limit="-89.4" upper_limit="1940.4"/>
                    <measurement group_id="O2" value="8.55" lower_limit="-78.5" upper_limit="281.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="719"/>
                    <count group_id="O2" value="346"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.42" lower_limit="-97.9" upper_limit="1430.3"/>
                    <measurement group_id="O2" value="8.57" lower_limit="-76.3" upper_limit="452.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FEPO4 - Change at Week 24</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>=0.288</p_value>
            <method>Van Elteren Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FEPO4 - Change at Week 48</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>=0.148</p_value>
            <method>Van Elteren Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Virologic Response Based on HIV-1 RNA Less Than (&lt;)20, &lt;50, and &lt;200 Copies/mL Threshold at Week 48 as Defined by the Food and Drug Administration (FDA) Snapshot Approach</title>
        <description>Percentage of participants with virologic response based on HIV-1 RNA &lt;20, &lt;50, and &lt;200 copies/mL threshold were analyzed at Week 48 using FDA snapshot approach. FDA Snapshot approach analysis was based on the last observed viral load data: virologic response was defined as HIV-1 RNA &lt;20/50/200 copies/mL (observed case).</description>
        <time_frame>Week 48</time_frame>
        <population>ITT analysis set included all the participants who were randomized and received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF</title>
            <description>Participants received a single fixed dose combination (FDC) tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF tablet), orally once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received a boosted protease inhibitor (bPI) (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) combined with emtricitabine/tenofovir disoproxil fumarate (F/TDF) up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Virologic Response Based on HIV-1 RNA Less Than (&lt;)20, &lt;50, and &lt;200 Copies/mL Threshold at Week 48 as Defined by the Food and Drug Administration (FDA) Snapshot Approach</title>
          <description>Percentage of participants with virologic response based on HIV-1 RNA &lt;20, &lt;50, and &lt;200 copies/mL threshold were analyzed at Week 48 using FDA snapshot approach. FDA Snapshot approach analysis was based on the last observed viral load data: virologic response was defined as HIV-1 RNA &lt;20/50/200 copies/mL (observed case).</description>
          <population>ITT analysis set included all the participants who were randomized and received at least 1 dose of study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="763"/>
                <count group_id="O2" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;20 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.8" lower_limit="87.4" upper_limit="91.8"/>
                    <measurement group_id="O2" value="88.4" lower_limit="84.7" upper_limit="91.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;50 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.9" lower_limit="93.1" upper_limit="96.3"/>
                    <measurement group_id="O2" value="93.7" lower_limit="90.7" upper_limit="95.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;200 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.0" lower_limit="93.2" upper_limit="96.5"/>
                    <measurement group_id="O2" value="94.2" lower_limit="91.3" upper_limit="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Virologic Response Based on HIV-1 RNA &lt;20, &lt;50, and &lt;200 Copies/mL Threshold at Week 48 as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm</title>
        <description>Percentage of participants with virologic response based on HIV-1 RNA &lt;20, &lt;50, and &lt;200 copies/mL threshold were analyzed at Week 48 using TLOVR algorithm approach. TLOVR was defined as sustained HIV-1 RNA &lt;20/50/200 copies/mL.</description>
        <time_frame>Week 48</time_frame>
        <population>ITT analysis set included all the participants who were randomized and received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF</title>
            <description>Participants received a single fixed dose combination (FDC) tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF tablet), orally once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received a boosted protease inhibitor (bPI) (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) combined with emtricitabine/tenofovir disoproxil fumarate (F/TDF) up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Virologic Response Based on HIV-1 RNA &lt;20, &lt;50, and &lt;200 Copies/mL Threshold at Week 48 as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm</title>
          <description>Percentage of participants with virologic response based on HIV-1 RNA &lt;20, &lt;50, and &lt;200 copies/mL threshold were analyzed at Week 48 using TLOVR algorithm approach. TLOVR was defined as sustained HIV-1 RNA &lt;20/50/200 copies/mL.</description>
          <population>ITT analysis set included all the participants who were randomized and received at least 1 dose of study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="763"/>
                <count group_id="O2" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;20 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.0" lower_limit="83.3" upper_limit="88.4"/>
                    <measurement group_id="O2" value="83.6" lower_limit="79.5" upper_limit="87.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;50 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.7" lower_limit="91.7" upper_limit="95.3"/>
                    <measurement group_id="O2" value="92.9" lower_limit="89.8" upper_limit="95.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;200 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.4" lower_limit="93.7" upper_limit="96.8"/>
                    <measurement group_id="O2" value="94.7" lower_limit="91.9" upper_limit="96.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cluster of Differentiation 4 Plus (CD4+) Cell Count at Weeks 24 and 48</title>
        <description>Change from baseline in CD4+ cell count was assessed at Weeks 24 and 48.</description>
        <time_frame>Baseline, Weeks 24 and 48</time_frame>
        <population>ITT analysis set included all the participants who were randomized and received at least 1 dose of study treatment. Here ‘n’ specifies those participants who were analyzed for this endpoint at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF</title>
            <description>Participants received a single fixed dose combination (FDC) tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF tablet), orally once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received a boosted protease inhibitor (bPI) (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) combined with emtricitabine/tenofovir disoproxil fumarate (F/TDF) up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cluster of Differentiation 4 Plus (CD4+) Cell Count at Weeks 24 and 48</title>
          <description>Change from baseline in CD4+ cell count was assessed at Weeks 24 and 48.</description>
          <population>ITT analysis set included all the participants who were randomized and received at least 1 dose of study treatment. Here ‘n’ specifies those participants who were analyzed for this endpoint at given time point.</population>
          <units>Cells per cubic millimeter (cells/mm^3)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="763"/>
                <count group_id="O2" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="763"/>
                    <count group_id="O2" value="378"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="653.3" spread="9.12"/>
                    <measurement group_id="O2" value="641.7" spread="13.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="731"/>
                    <count group_id="O2" value="362"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" spread="5.99"/>
                    <measurement group_id="O2" value="8.5" spread="7.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="722"/>
                    <count group_id="O2" value="351"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.0" spread="5.97"/>
                    <measurement group_id="O2" value="9.1" spread="8.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Treatment Adherence of Greater Than (&gt;)95 Percent (%) (Approach 1) Through Week 48</title>
        <description>Treatment adherence (defined as adherence of &gt;95%) was assessed by the drug accountability cumulative through Week 48 (Approach 1).</description>
        <time_frame>Through Week 48</time_frame>
        <population>ITT analysis set included all the participants who were randomized and received at least 1 dose of study treatment. Here, N (number of participants analyzed) indicates the number of participants evaluable for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF</title>
            <description>Participants received a single fixed dose combination (FDC) tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF tablet), orally once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received a boosted protease inhibitor (bPI) (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) combined with emtricitabine/tenofovir disoproxil fumarate (F/TDF) up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment Adherence of Greater Than (&gt;)95 Percent (%) (Approach 1) Through Week 48</title>
          <description>Treatment adherence (defined as adherence of &gt;95%) was assessed by the drug accountability cumulative through Week 48 (Approach 1).</description>
          <population>ITT analysis set included all the participants who were randomized and received at least 1 dose of study treatment. Here, N (number of participants analyzed) indicates the number of participants evaluable for this endpoint.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.6"/>
                    <measurement group_id="O2" value="85.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Treatment Adherence of &gt;95% (Approach 2) Through Week 48</title>
        <description>Treatment adherence (defined as adherence of &gt;95%) was assessed by the drug accountability cumulative treatment adherence up to time point where not more than one bottle was missing, or if available, through Week 48, whichever came sooner (Approach 2).</description>
        <time_frame>Through Week 48</time_frame>
        <population>ITT analysis set included all the participants who were randomized and received at least 1 dose of study treatment. Here, 'N' (number of participants analyzed) indicates the number of participants evaluable for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF</title>
            <description>Participants received a single fixed dose combination (FDC) tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF tablet), orally once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received a boosted protease inhibitor (bPI) (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) combined with emtricitabine/tenofovir disoproxil fumarate (F/TDF) up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment Adherence of &gt;95% (Approach 2) Through Week 48</title>
          <description>Treatment adherence (defined as adherence of &gt;95%) was assessed by the drug accountability cumulative treatment adherence up to time point where not more than one bottle was missing, or if available, through Week 48, whichever came sooner (Approach 2).</description>
          <population>ITT analysis set included all the participants who were randomized and received at least 1 dose of study treatment. Here, 'N' (number of participants analyzed) indicates the number of participants evaluable for this endpoint.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="631"/>
                <count group_id="O2" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.7"/>
                    <measurement group_id="O2" value="77.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Resistance to Study Drug</title>
        <description>HIV-1 genotypes were analyzed from samples of participants with confirmed virologic rebound (virologic rebound was defined as: confirmed HIV-1 RNA &gt;=50 copies/mL up to, and including the upper bound of the Week 48 window) and with HIV-1 RNA value greater than or equal to (&gt;=)400 copies/mL or who discontinued with last HIV-1 RNA &gt;=400 copies/mL. Number of participants who developed resistance to any of the study drug was determined.</description>
        <time_frame>Up to Week 48</time_frame>
        <population>The ITT population with confirmed virologic rebound and with HIV-1 RNA value &gt;=400 copies/mL was analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF</title>
            <description>Participants received a single fixed dose combination (FDC) tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF tablet), orally once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received a boosted protease inhibitor (bPI) (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) combined with emtricitabine/tenofovir disoproxil fumarate (F/TDF) up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Resistance to Study Drug</title>
          <description>HIV-1 genotypes were analyzed from samples of participants with confirmed virologic rebound (virologic rebound was defined as: confirmed HIV-1 RNA &gt;=50 copies/mL up to, and including the upper bound of the Week 48 window) and with HIV-1 RNA value greater than or equal to (&gt;=)400 copies/mL or who discontinued with last HIV-1 RNA &gt;=400 copies/mL. Number of participants who developed resistance to any of the study drug was determined.</description>
          <population>The ITT population with confirmed virologic rebound and with HIV-1 RNA value &gt;=400 copies/mL was analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Predose (Trough) Plasma Concentration (C0h) of Darunavir</title>
        <description>Predose (trough) plasma concentration (C0h) of darunavir was determined. Pharmacokinetic (PK) data was only analyzed for participants in the D/C/F/TAF group as per planned analysis.</description>
        <time_frame>Predose at Weeks 2, 4, 8, 12, 24, 36, and 48</time_frame>
        <population>The PK analysis set included all participants randomized to D/C/F/TAF group and received at least 1 dose of study drug in study, and for whom plasma concentration data of any analytes of interest were available. Here ‘n’ specifies participants who were analyzed for this endpoint at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF</title>
            <description>Participants received a single fixed dose combination (FDC) tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF tablet), orally once daily up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Predose (Trough) Plasma Concentration (C0h) of Darunavir</title>
          <description>Predose (trough) plasma concentration (C0h) of darunavir was determined. Pharmacokinetic (PK) data was only analyzed for participants in the D/C/F/TAF group as per planned analysis.</description>
          <population>The PK analysis set included all participants randomized to D/C/F/TAF group and received at least 1 dose of study drug in study, and for whom plasma concentration data of any analytes of interest were available. Here ‘n’ specifies participants who were analyzed for this endpoint at given time point.</population>
          <units>Nanogram per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="750"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1775.29" spread="1698.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1732.00" spread="1389.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1910.30" spread="1501.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1643.38" spread="1328.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="112"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2022.99" spread="1965.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1806.37" spread="1669.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1899.79" spread="1833.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Serum Procollagen 1 N-Terminal Propeptide (P1NP) and Serum Collagen Type 1 Beta Carboxy Telopeptide (CTX) Levels at Weeks 24 and 48</title>
        <description>Percent change from baseline in bone biomarkers: P1NP and CTX was assessed at Weeks 24 and 48.</description>
        <time_frame>Baseline, Weeks 24 and 48</time_frame>
        <population>The bone investigation substudy (BIS) analysis set included all participants who were randomized and received at least 1 dose of study drug in the study, and had at least one postbaseline value for biomarker data. Here ‘n’ specifies participants who were analyzed for this endpoint at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF</title>
            <description>Participants received a single fixed dose combination (FDC) tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF tablet), orally once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received a boosted protease inhibitor (bPI) (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) combined with emtricitabine/tenofovir disoproxil fumarate (F/TDF) up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Serum Procollagen 1 N-Terminal Propeptide (P1NP) and Serum Collagen Type 1 Beta Carboxy Telopeptide (CTX) Levels at Weeks 24 and 48</title>
          <description>Percent change from baseline in bone biomarkers: P1NP and CTX was assessed at Weeks 24 and 48.</description>
          <population>The bone investigation substudy (BIS) analysis set included all participants who were randomized and received at least 1 dose of study drug in the study, and had at least one postbaseline value for biomarker data. Here ‘n’ specifies participants who were analyzed for this endpoint at given time point.</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>P1NP: Percent change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                    <count group_id="O2" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.971" spread="1.8818"/>
                    <measurement group_id="O2" value="-0.027" spread="2.7325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P1NP: Percent change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.752" spread="1.8960"/>
                    <measurement group_id="O2" value="-3.751" spread="2.6988"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CTX: Percent change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="190"/>
                    <count group_id="O2" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.772" spread="2.2575"/>
                    <measurement group_id="O2" value="16.312" spread="3.8855"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CTX: Percent change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="185"/>
                    <count group_id="O2" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.517" spread="3.2325"/>
                    <measurement group_id="O2" value="5.433" spread="4.1118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Parathyroid Hormone (PTH) at Weeks 24 and 48</title>
        <description>Percent change from baseline in bone biomarker: PTH was assessed at Weeks 24 and 48.</description>
        <time_frame>Baseline, Weeks 24 and 48</time_frame>
        <population>The bone investigation substudy (BIS) analysis set included all participants who were randomized and received at least 1 dose of study drug in the study, and had at least one postbaseline value for biomarker data. Here ‘n’ specifies participants who were analyzed for this endpoint at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF</title>
            <description>Participants received a single fixed dose combination (FDC) tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF tablet), orally once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received a boosted protease inhibitor (bPI) (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) combined with emtricitabine/tenofovir disoproxil fumarate (F/TDF) up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Parathyroid Hormone (PTH) at Weeks 24 and 48</title>
          <description>Percent change from baseline in bone biomarker: PTH was assessed at Weeks 24 and 48.</description>
          <population>The bone investigation substudy (BIS) analysis set included all participants who were randomized and received at least 1 dose of study drug in the study, and had at least one postbaseline value for biomarker data. Here ‘n’ specifies participants who were analyzed for this endpoint at given time point.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="199"/>
                    <count group_id="O2" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.092" spread="2.5941"/>
                    <measurement group_id="O2" value="12.034" spread="4.1777"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.510" spread="2.5375"/>
                    <measurement group_id="O2" value="9.436" spread="4.4784"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in 25-hydroxy Vitamin D at Weeks 24 and 48</title>
        <description>Percent change from baseline in bone biomarker: 25-hydroxy vitamin D was assessed at Weeks 24 and 48.</description>
        <time_frame>Baseline, Weeks 24 and 48</time_frame>
        <population>The bone investigation substudy (BIS) analysis set included all participants who were randomized and received at least 1 dose of study drug in the study, and had at least one postbaseline value for biomarker data. Here ‘n’ specifies participants who were analyzed for this endpoint at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF</title>
            <description>Participants received a single fixed dose combination (FDC) tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF tablet), orally once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received a boosted protease inhibitor (bPI) (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) combined with emtricitabine/tenofovir disoproxil fumarate (F/TDF) up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in 25-hydroxy Vitamin D at Weeks 24 and 48</title>
          <description>Percent change from baseline in bone biomarker: 25-hydroxy vitamin D was assessed at Weeks 24 and 48.</description>
          <population>The bone investigation substudy (BIS) analysis set included all participants who were randomized and received at least 1 dose of study drug in the study, and had at least one postbaseline value for biomarker data. Here ‘n’ specifies participants who were analyzed for this endpoint at given time point.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="5.06"/>
                    <measurement group_id="O2" value="4.2" spread="6.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                    <count group_id="O2" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2" spread="5.51"/>
                    <measurement group_id="O2" value="24.9" spread="7.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Spine and Hip Bone Mineral Density (BMD) at Weeks 24 and 48</title>
        <description>Percent change from baseline in spine and hip BMD was assessed at Weeks 24 and 48.</description>
        <time_frame>Baseline, Weeks 24 and 48</time_frame>
        <population>The bone investigation substudy (BIS) analysis set included all participants who were randomized and received at least 1 dose of study drug in the study, and had at least one postbaseline value for bone mineral density (BMD) data. Here ‘n’ specifies participants who were analyzed for this endpoint at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF</title>
            <description>Participants received a single fixed dose combination (FDC) tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF tablet), orally once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received a boosted protease inhibitor (bPI) (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) combined with emtricitabine/tenofovir disoproxil fumarate (F/TDF) up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Spine and Hip Bone Mineral Density (BMD) at Weeks 24 and 48</title>
          <description>Percent change from baseline in spine and hip BMD was assessed at Weeks 24 and 48.</description>
          <population>The bone investigation substudy (BIS) analysis set included all participants who were randomized and received at least 1 dose of study drug in the study, and had at least one postbaseline value for bone mineral density (BMD) data. Here ‘n’ specifies participants who were analyzed for this endpoint at given time point.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Spine BMD: Percent change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="192"/>
                    <count group_id="O2" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.55" spread="0.276"/>
                    <measurement group_id="O2" value="0.18" spread="0.342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spine BMD: Percent change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="192"/>
                    <count group_id="O2" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.06" spread="0.324"/>
                    <measurement group_id="O2" value="0.01" spread="0.391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hip BMD: Percent change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="0.230"/>
                    <measurement group_id="O2" value="0.00" spread="0.279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hip BMD: Percent change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="188"/>
                    <count group_id="O2" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="0.244"/>
                    <measurement group_id="O2" value="-0.08" spread="0.288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Spine BMD: Percent change at Week 24</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.37</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.340</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.697</ci_lower_limit>
            <ci_upper_limit>2.037</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Spine BMD: Percent change at Week 48</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>2.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.390</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.277</ci_lower_limit>
            <ci_upper_limit>2.814</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hip BMD: Percent change at Week 24</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>=0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.90</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.272</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.366</ci_lower_limit>
            <ci_upper_limit>1.436</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hip BMD: Percent change at Week 48</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.70</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.280</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.144</ci_lower_limit>
            <ci_upper_limit>2.248</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Bone Mineral Density (BMD) T-Score at Weeks 24 and 48</title>
        <description>Change from baseline in spine, hip, and femoral neck BMD T-Score was assessed at Week 24 and 48. T-score values &gt;= -1.0 were considered normal, T-score values &lt; -1.0 to -2.5 indicate osteopenia and T-score values &lt; -2.5 indicate osteoporosis.</description>
        <time_frame>Baseline, Weeks 24 and 48</time_frame>
        <population>The bone investigation substudy (BIS) analysis set included all participants who were randomized and received at least 1 dose of study drug in the study, and had at least one postbaseline value for BMD data. Here ‘n’ specifies those participants who were analyzed for this endpoint at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF</title>
            <description>Participants received a single fixed dose combination (FDC) tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF tablet), orally once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received a boosted protease inhibitor (bPI) (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) combined with emtricitabine/tenofovir disoproxil fumarate (F/TDF) up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Bone Mineral Density (BMD) T-Score at Weeks 24 and 48</title>
          <description>Change from baseline in spine, hip, and femoral neck BMD T-Score was assessed at Week 24 and 48. T-score values &gt;= -1.0 were considered normal, T-score values &lt; -1.0 to -2.5 indicate osteopenia and T-score values &lt; -2.5 indicate osteoporosis.</description>
          <population>The bone investigation substudy (BIS) analysis set included all participants who were randomized and received at least 1 dose of study drug in the study, and had at least one postbaseline value for BMD data. Here ‘n’ specifies those participants who were analyzed for this endpoint at given time point.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Spine BMD T-score: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="206"/>
                    <count group_id="O2" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.713" spread="0.0850"/>
                    <measurement group_id="O2" value="-0.467" spread="0.1260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spine BMD T-score: Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="192"/>
                    <count group_id="O2" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.102" spread="0.0172"/>
                    <measurement group_id="O2" value="-0.033" spread="0.0253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spine BMD T-score: Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="192"/>
                    <count group_id="O2" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.132" spread="0.0217"/>
                    <measurement group_id="O2" value="-0.063" spread="0.0264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hip BMD T-score: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="204"/>
                    <count group_id="O2" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.575" spread="0.0643"/>
                    <measurement group_id="O2" value="-0.484" spread="0.0839"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hip BMD T-score: Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.037" spread="0.0108"/>
                    <measurement group_id="O2" value="-0.024" spread="0.0144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hip BMD T-score: Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="188"/>
                    <count group_id="O2" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.095" spread="0.0122"/>
                    <measurement group_id="O2" value="-0.016" spread="0.0139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Femoral Neck BMD T-score: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="204"/>
                    <count group_id="O2" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.782" spread="0.0625"/>
                    <measurement group_id="O2" value="-0.699" spread="0.0899"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Femoral Neck BMD T-score: Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.019" spread="0.0128"/>
                    <measurement group_id="O2" value="-0.044" spread="0.0183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Femoral Neck BMD T-score: Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="188"/>
                    <count group_id="O2" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.039" spread="0.0146"/>
                    <measurement group_id="O2" value="-0.039" spread="0.0214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Week 48</time_frame>
      <desc>Safety was performed using intent-to-treat (ITT) analysis set which included all the participants who were randomized and received at least 1 dose of study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>D/C/F/TAF</title>
          <description>Participants received a single fixed dose combination (FDC) tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF tablet), orally once daily up to Week 48.</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Participants received a boosted protease inhibitor (bPI) (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) combined with emtricitabine/tenofovir disoproxil fumarate (F/TDF) up to Week 48.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 19.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Herpes simplex meningitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Lymphogranuloma venereum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Perineal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Syphilis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Biopsy lymph gland</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Retinal melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device breakage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Bladder mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometrial thickening</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA Version 19.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="622" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="310" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Neutrophilia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Cardiac flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Dermoid cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pulmonary arteriovenous fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Type V hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Deafness bilateral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Deafness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Ear disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Ear pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Eustachian tube dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Excessive cerumen production</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Middle ear effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Tympanic membrane disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Tympanic membrane hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal suppression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hypogonadism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Eczema eyelids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Eye swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Eyelid disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Eyelid haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Eyelid pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Lacrimal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Ocular hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Presbyopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Abdominal tenderness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Acquired oesophageal web</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Aerophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Anal incontinence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Anal polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Anal pruritus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Anal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Anogenital dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Anorectal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Anorectal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Bowel movement irregularity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Breath odour</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Dental discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Faeces soft</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Gastric disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Gastrointestinal polyp haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Gingival recession</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Gingival swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Leukoplakia oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Oral disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Oral pigmentation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Palatal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pancreatic insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pigmentation lip</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Rectal discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Rectal fissure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Tongue disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Tongue oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Tooth disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Tooth impacted</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Energy increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Haemorrhagic cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Nodule</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Suprapubic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Temperature regulation disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Xerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess jaw</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Abscess oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Acute hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Amoebiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Anal chlamydia infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Angular cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Anorectal human papilloma virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Bacterial vaginosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Balanitis candida</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Blastocystis infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Carbuncle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Chikungunya virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Chlamydial infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Conjunctivitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Dermatophytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Dermo-hypodermitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Genital herpes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Genital herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Genital infection fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Giardiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Gingival abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Gonorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Herpes simplex hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Herpes zoster infection neurological</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Infected bite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Infected dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Latent syphilis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Lymphogranuloma venereum</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Nasal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Oral fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Oropharyngeal gonococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Papilloma viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pharyngeal chlamydia infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pharyngitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Primary syphilis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Proctitis chlamydial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Proctitis gonococcal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Purulent discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pyuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Rhinovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Secondary syphilis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Sexually transmitted disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Shigella infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Spirochaetal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Staphylococcal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Syphilis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Syphilis genital</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Tinea versicolour</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Trichomoniasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Ureteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Urethritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Urethritis chlamydial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Urethritis gonococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Urinary tract infection enterococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Vaginitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Vaginitis gardnerella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Viral rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Chemical eye injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Ear canal abrasion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Epicondylitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Exposure to communicable disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Exposure to toxic agent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Incision site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Medication error</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Post procedural discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Post-traumatic neck syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Post-traumatic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Procedural dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Splinter</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Alpha-1 acid glycoprotein decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Beta 2 microglobulin increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Beta 2 microglobulin urine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Beta 2 microglobulin urine increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Blood parathyroid hormone increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Blood pressure diastolic increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Bone density decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Breath sounds abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>C-telopeptide increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Carotid bruit</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Creatinine renal clearance decreased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Cryptococcus test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Cystatin C increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Eosinophil count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Faecal calprotectin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Intestinal transit time decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Mycobacterium tuberculosis complex test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Neutrophil count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Occult blood positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Serum ferritin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Serum procollagen type I N-terminal propeptide increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Urine leukocyte esterase positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Vitamin D decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Folate deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Glucose tolerance impaired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hyperchylomicronaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Lactose intolerance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Arthritis reactive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Metatarsalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Muscle contracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Muscle fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Periostitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Peripheral arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Scoliosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Tendon calcification</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Tendon pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Torticollis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Trigger finger</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acrochordon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma stage 0</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Haemangioma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Lipofibroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Neoplasm skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Oral papilloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Ovarian neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Cervical radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Dizziness exertional</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Drug withdrawal headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hyperaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hypogeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Irregular sleep phase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Occipital neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Sacral radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Sensory loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Thoracic outlet syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Tunnel vision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Adjustment disorder with depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Attention deficit/hyperactivity disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Binge drinking</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Claustrophobia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Depressive symptom</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Dysphoria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Euphoric mood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Gender dysphoria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Grief reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hallucination, visual</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Initial insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Loss of libido</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Persistent depressive disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Substance abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Tearfulness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Tobacco withdrawal symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder spasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Costovertebral angle tenderness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Crystalluria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Cystitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Glycosuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Leukocyturia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Micturition disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Nephropathy toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Renal tubular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Terminal dribbling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Urethral discharge</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Urethral pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Urine odour abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Balanoposthitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Genital haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Genital lesion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Genital rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Haematospermia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Menometrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Menopausal symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Penile discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Penis disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pruritus genital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Retrograde ejaculation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Scrotal angiokeratoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Scrotal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Scrotal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Testicular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Testicular mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Catarrh</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Paranasal sinus hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pharyngeal erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pharyngeal ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Rales</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Respiratory symptom</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Use of accessory respiratory muscles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Dandruff</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Facial wasting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hand dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Idiopathic urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Intertrigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Lichen planus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Lipodystrophy acquired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Miliaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Onychomadesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Papule</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pigmentation disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Rosacea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Skin discolouration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Skin mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Vitiligo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Hearing aid user</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Menopause</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Tobacco user</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic dilatation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="763"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The limitation of the study was the open-label design.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Medical Officer</name_or_title>
      <organization>Janssen Research &amp; Development</organization>
      <phone>844-434-4210</phone>
      <email>ClinicalTrialDisclosure@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

